848192-93-8

Usage

Uses

Used in Pharmaceutical Industry:
3-cyclopropylazetidin-3-ol hydrochloride is used as a pharmaceutical intermediate for the synthesis of various drugs, leveraging its unique structural properties to enhance drug development and therapeutic efficacy.
Used in Medicinal Chemistry Research:
3-cyclopropylazetidin-3-ol hydrochloride is utilized as a valuable building block in medicinal chemistry, contributing to the creation of new pharmacologically active compounds for a range of therapeutic applications.
Used in Neurological Disorders Treatment:
3-cyclopropylazetidin-3-ol hydrochloride is studied for its potential as an anticonvulsant, indicating its use in the treatment of neurological disorders, particularly those involving seizure control.
Used in Neurotransmitter Regulation:
As an inhibitor of GABA uptake, 3-cyclopropylazetidin-3-ol hydrochloride is explored for its role in modulating neurotransmitter levels, which could have implications for the treatment of conditions related to neurotransmitter imbalances.

InChI:InChI=1/C6H11NO.ClH/c8-6(3-7-4-6)5-1-2-5;/h5,7-8H,1-4H2;1H

Upstream product

• 848192-90-5 1-benzhydryl-3-cyclopropyl-azetidin-3-ol 

Relevant academic research and scientific papers

PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA

Provided are compounds of formula (I) or a pharmaceutically acceptable salts or stereoisomer thereof, which are PI3K-delta inhibitors, and are useful for the treatment of PI3K-delts-mediated diseases such as inflammation, asthma, COPD and cancer.

Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate

Carboxamide pyrazinyloxy benzoxaboroles were investigated with the goal to identify a molecule with satisfactory antimalarial activity, physicochemical properties, pharmacokinetic profile, in vivo efficacy, and safety profile. This optimization effort discovered 46, which met our target candidate profile. Compound 46 had excellent activity against cultured Plasmodium falciparum, and in vivo against P. falciparum and P. berghei in infected mice. It exhibited good PK properties in mice, rats, and dogs. It was highly active against the other 11 P. falciparum strains, which are mostly resistant to chloroquine and pyrimethamine. The rapid parasite in vitro reduction and in vivo parasite clearance profile of 46 were similar to those of artemisinin and chloroquine, two rapid-acting antimalarials. It was nongenotoxic in an Ames assay, an in vitro micronucleus assay, and an in vivo rat micronucleus assay when dosed orally up to 2000 mg/kg. The combined properties of this novel benzoxaborole support its progression to preclinical development.

TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE

A compound represented by the general formula (1) [X1 and X2 represent hydrogen atom, a halogen atom, hydroxyl group and the like, R1 represents a phenyl group, R2 represents an alkyl group, an alkenyl group, or

Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

AZETIDINYL QUINOLONES AS ANTIBACTERIAL AGENTS

Compounds of formula (I) and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula (I) as well as pharmaceutically acceptable compositions comprising compounds of formula (I). Compoun

QUINAZOLINE-2, 4-DIONES AS ANTIBACTERIAL AGENTS

Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of